Kano

Kano Therapeutics, founded at MIT, bridges gene editing and full gene replacement, paving the way for the widespread use of single-stranded DNA payloads in cell and gene therapies. The company is developing and co-developing therapies capable of safely, effectively, and flexibly correcting DNA segments of lengths that current editing technologies cannot address.